Remote Monitoring in Decentralized Trials
Less than 5% of patients with cancer enroll in a clinical trial, partly due to financial and logistic burdens. To assess the current global state of adoption of decentralized trial technologies, a survey was directed to 8 global biopharmaceutical companies, representing 33% of the oncology marketplace.
The results showed that while remote monitoring and data collection technologies are already being adopted across clinical trials, it’s significantly lower than where respondents want it to be within 5 years.
This represents an opportunity—for technology like remote ECG monitoring—to rapidly improve the patient experience in cancer trials, broaden access to clinical trials, and improve access to healthcare.
Key Takeaways:
- There is a substantial shift in the adoption of decentralized trial operations by pharmaceutical companies
- Telemedicine, digitally enabled recruitment, electronic diaries, and electronic clinical outcome assessments were identified as the most effective technologies for advancing patient centricity within trials in the short term
- Over the long term, visits in local physician networks, digitally enabled recruitment, and the use of imaging sites near patients and mobile imaging services were identified as the most effective in improving oncology patient experience
- Adoption of remote monitoring is important yet lagging behind
Clinical Evidence
Remote Monitoring in Decentralized Trials
JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.
Handheld 6-Lead Validated for QT Monitoring
JAMAnetwork.com | A 6-lead device transforms cardiac care in resource-limited settings. This study in JAMA highlights its accuracy in monitoring QT intervals, reducing standard 12-lead ECG dependency, and easing access to cardiac care.
KardiaMobile® 6L vs 12-lead ECG Impact on Clinic Time
Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12-lead ECG systems. This study published in Wiley highlights how KardiaMobile 6L minimizes the need for frequent conventional 12-lead use.